Raffaele Califano
@caliraf
Followers
1K
Following
2K
Statuses
1K
Thoracic Oncologist @TheChristieNHS, Honorary Professor @UoM_DCS . Member @myesmo Educational Publication WG. Views are my own No DMs or medical advice given.
Manchester, England
Joined March 2011
I am sorry I cannot respond to specific requests for medical advice or DMs
0
0
1
RT @g_mountzios: A great task force, a great bunch of people to work with !! Honored to work and serve in the Educational Publications Work…
0
4
0
RT @JournalCancer: In the phase 2 DeLLphi-301 trial, tarlatamab showed durable responses in #SCLC, but adverse events management is critica…
0
8
0
RT @APassaroMD: 🔑 🇪🇺 #PressRelease EMA CHMP recommends subcutaneous amivantamab (Q2W) for the treatment of patients with advanced EGFR-mut…
0
15
0
RT @StephenVLiu: Phase III EXCLAIM-2 trial of 1L mobocertinib vs chemotherapy in #EGFR exon 20 NSCLC @JCO_ASCO. Negative trial: PFS 9.6m in…
0
31
0
RT @StephenVLiu: The Phase 2b REZILIENT1 study of zipalertinib (CLN-081/TAS6417) met its primary endpoint of response rate in patients with…
0
5
0
RT @StephenVLiu: Phase 2 SKIPPirr study now @JTOonline: premedication regimen of oral dexamethasone 8mg BID on C1D-2, C1D-1, and morning of…
0
22
0
Please see our data on 1L osimertinib compared by earlier gen TKIs @irrandulfe
@DrColinLindsay
@lauramolinerj @ChristieLibrary @mathew_carter1
@FabioGomes_Go @fblackhall
0
3
7
RT @APassaroMD: 🚨Major breakthrough from #PressRelease The MARIPOSA study reports a statistically significant and clinically meaningful im…
0
24
0
RT @StephenVLiu: CHRYSALIS-2 Cohort A: amivantamab + lazertinib in #EGFR NSCLC after osimertinib and chemotherapy @JTOonline (n=162). BICR…
0
37
0
RT @DrJNaidoo: Ph II TROPICS-03 trial: Sacituzumab Govitecan (TROP2 ADC) in 2L SCLC @JTOonline: - 43pts - ORR 41.9% (35% plt-resistant, 48…
0
20
0
RT @hsbalata: Fantastic milestone for the #TargetedLungHealthChecks: >5,000 lung cancers detected since inception, >75% at an early stage.…
0
22
0
Honoured to have been Derek Crowther’s last ‘Senior Registrar’. Forever grateful for his appointment as a CRC Clinical Reseach Fellow in his Dept in 1989, which shaped my career. His pioneering legacy in medical oncology had left an indelible mark in UK.
0
0
2
RT @ProfSiowMingLee: Honoured to have been Derek Crowther’s last ‘Senior Registrar’. Forever grateful for his appointment as a CRC Clinical…
0
2
0
0
1
0